161 related articles for article (PubMed ID: 34440787)
21. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
22. Adoptive cytotoxic T lymphocyte therapy triggers a counter-regulatory immunosuppressive mechanism via recruitment of myeloid-derived suppressor cells.
Hosoi A; Matsushita H; Shimizu K; Fujii S; Ueha S; Abe J; Kurachi M; Maekawa R; Matsushima K; Kakimi K
Int J Cancer; 2014 Apr; 134(8):1810-22. PubMed ID: 24150772
[TBL] [Abstract][Full Text] [Related]
23. 6-Thioguanine-loaded polymeric micelles deplete myeloid-derived suppressor cells and enhance the efficacy of T cell immunotherapy in tumor-bearing mice.
Jeanbart L; Kourtis IC; van der Vlies AJ; Swartz MA; Hubbell JA
Cancer Immunol Immunother; 2015 Aug; 64(8):1033-46. PubMed ID: 25982370
[TBL] [Abstract][Full Text] [Related]
24. Radiotherapy combined with intratumoral dendritic cell vaccination enhances the therapeutic efficacy of adoptive T-cell transfer.
Teitz-Tennenbaum S; Li Q; Davis MA; Wilder-Romans K; Hoff J; Li M; Chang AE
J Immunother; 2009; 32(6):602-12. PubMed ID: 19483649
[TBL] [Abstract][Full Text] [Related]
25. Priming of naive CD8+ T cells in the presence of IL-12 selectively enhances the survival of CD8+CD62Lhi cells and results in superior anti-tumor activity in a tolerogenic murine model.
Díaz-Montero CM; El Naggar S; Al Khami A; El Naggar R; Montero AJ; Cole DJ; Salem ML
Cancer Immunol Immunother; 2008 Apr; 57(4):563-72. PubMed ID: 17726606
[TBL] [Abstract][Full Text] [Related]
26. Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice.
Klebanoff CA; Gattinoni L; Palmer DC; Muranski P; Ji Y; Hinrichs CS; Borman ZA; Kerkar SP; Scott CD; Finkelstein SE; Rosenberg SA; Restifo NP
Clin Cancer Res; 2011 Aug; 17(16):5343-52. PubMed ID: 21737507
[TBL] [Abstract][Full Text] [Related]
27. T-Cell Therapy Enabling Adenoviruses Coding for IL2 and TNFα Induce Systemic Immunomodulation in Mice With Spontaneous Melanoma.
Tähtinen S; Blattner C; Vähä-Koskela M; Saha D; Siurala M; Parviainen S; Utikal J; Kanerva A; Umansky V; Hemminki A
J Immunother; 2016; 39(9):343-354. PubMed ID: 27741089
[TBL] [Abstract][Full Text] [Related]
28. Effector CD8+ T-cell Engraftment and Antitumor Immunity in Lymphodepleted Hosts Is IL7Rα Dependent.
Johnson CB; Riesenberg BP; May BR; Gilreath SC; Li G; Staveley-O'Carroll KF; Garrett-Mayer E; Mehrotra S; Cole DJ; Rubinstein MP
Cancer Immunol Res; 2015 Dec; 3(12):1364-74. PubMed ID: 26297711
[TBL] [Abstract][Full Text] [Related]
29. Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma.
Pilon-Thomas S; Mackay A; Vohra N; Mulé JJ
J Immunol; 2010 Apr; 184(7):3442-9. PubMed ID: 20194714
[TBL] [Abstract][Full Text] [Related]
30. Incubation of antigen-sensitized T lymphocytes activated with bryostatin 1 + ionomycin in IL-7 + IL-15 increases yield of cells capable of inducing regression of melanoma metastases compared to culture in IL-2.
Le HK; Graham L; Miller CH; Kmieciak M; Manjili MH; Bear HD
Cancer Immunol Immunother; 2009 Oct; 58(10):1565-76. PubMed ID: 19198835
[TBL] [Abstract][Full Text] [Related]
31. Lymphopenic condition enhanced the antitumor immunity of PD-1-knockout T cells mediated by CRISPR/Cas9 system in malignant melanoma.
Yang Z; Wu H; Lin Q; Wang X; Kang S
Immunol Lett; 2022 Oct; 250():15-22. PubMed ID: 36174769
[TBL] [Abstract][Full Text] [Related]
32. Immunotherapy of melanoma: a dichotomy in the requirement for IFN-gamma in vaccine-induced antitumor immunity versus adoptive immunotherapy.
Winter H; Hu HM; McClain K; Urba WJ; Fox BA
J Immunol; 2001 Jun; 166(12):7370-80. PubMed ID: 11390488
[TBL] [Abstract][Full Text] [Related]
33. Cellular and molecular requirements for rejection of B16 melanoma in the setting of regulatory T cell depletion and homeostatic proliferation.
Kline J; Zhang L; Battaglia L; Cohen KS; Gajewski TF
J Immunol; 2012 Mar; 188(6):2630-42. PubMed ID: 22312128
[TBL] [Abstract][Full Text] [Related]
34. Blocking TCR restimulation induced necroptosis in adoptively transferred T cells improves tumor control.
Kesarwani P; Chakraborty P; Gudi R; Chatterjee S; Scurti G; Toth K; Simms P; Husain M; Armeson K; Husain S; Garrett-Mayer E; Vasu C; Nishimura MI; Mehrotra S
Oncotarget; 2016 Oct; 7(43):69371-69383. PubMed ID: 27750220
[TBL] [Abstract][Full Text] [Related]
35. IL-18 synergizes with IL-7 to drive slow proliferation of naive CD8 T cells by costimulating self-peptide-mediated TCR signals.
Walsh MC; Pearce EL; Cejas PJ; Lee J; Wang LS; Choi Y
J Immunol; 2014 Oct; 193(8):3992-4001. PubMed ID: 25200954
[TBL] [Abstract][Full Text] [Related]
36. Immunoglobulin Fc fragment tagging allows strong activation of endogenous CD4 T cells to reshape the tumor milieu and enhance the antitumor effect of lentivector immunization.
Hong Y; Peng Y; Xiao H; Mi M; Munn D; He Y
J Immunol; 2012 May; 188(10):4819-27. PubMed ID: 22504640
[TBL] [Abstract][Full Text] [Related]
37. Augmentation versus inhibition: effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor.
Kjaergaard J; Peng L; Cohen PA; Drazba JA; Weinberg AD; Shu S
J Immunol; 2001 Dec; 167(11):6669-77. PubMed ID: 11714839
[TBL] [Abstract][Full Text] [Related]
38. Newcastle disease virus co-expressing interleukin 7 and interleukin 15 modified tumor cells as a vaccine for cancer immunotherapy.
Xu X; Sun Q; Mei Y; Liu Y; Zhao L
Cancer Sci; 2018 Feb; 109(2):279-288. PubMed ID: 29224228
[TBL] [Abstract][Full Text] [Related]
39. Enhanced tumor responses to dendritic cells in the absence of CD8-positive cells.
Ribas A; Wargo JA; Comin-Anduix B; Sanetti S; Schumacher LY; McLean C; Dissette VB; Glaspy JA; McBride WH; Butterfield LH; Economou JS
J Immunol; 2004 Apr; 172(8):4762-9. PubMed ID: 15067052
[TBL] [Abstract][Full Text] [Related]
40. Recovery from cyclophosphamide-induced lymphopenia results in expansion of immature dendritic cells which can mediate enhanced prime-boost vaccination antitumor responses in vivo when stimulated with the TLR3 agonist poly(I:C).
Salem ML; Díaz-Montero CM; Al-Khami AA; El-Naggar SA; Naga O; Montero AJ; Khafagy A; Cole DJ
J Immunol; 2009 Feb; 182(4):2030-40. PubMed ID: 19201856
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]